囊性纤维化进展:CFTR调节剂三联组合
本文综述了CFTR调节剂三联组合在囊性纤维化治疗中的进展。三联组合最初针对F508del变异开发,对许多其他CFTR变异也有效,适用于大多数但非全部CF患者。文章还回顾了CF的遗传基础、肺部病理及既往对症治疗手段。
要点
- CFTR调节剂三联组合革新了CF治疗,对多数CFTR变异有效。
- 并非所有CF患者均适用三联组合,需考虑变异类型。
- 肺部病变是CF主要死因,涉及黏液阻塞、炎症和感染。
核心结论
- CFTR调节剂三联组合已革新囊性纤维化治疗,对F508del及其他多种CFTR变异有效。
- 三联组合适用于大多数但非全部CF患者。
研究设计与样本
- 原文为综述,未报告系统检索范围与样本量。
主要发现
- CFTR缺陷减少上皮氯离子和碳酸氢盐转运,导致多器官疾病。
- 肺部疾病是CF主要死因,涉及高黏弹性黏液、慢性炎症和细菌感染,可进展为呼吸衰竭。
- 数十年来CF护理进展主要来自对症治疗优化,如气道清除、营养管理、抗生素和肺移植转诊。
临床怎么用
- 临床可考虑对符合变异条件的CF患者使用CFTR调节剂三联组合。
- 应继续优化气道清除、营养支持、抗生素等对症治疗。
局限性
- 原文未报告系统检索策略及纳入研究细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Triple combinations of CFTR modulators have revolutionised the care of people with CF. Initially developed for the F508del variant, these drugs are effective in many other CFTR variants, making them suitable for most, but not all, people with CF. https://bit.ly/49yHjha Cystic fibrosis (CF) is a autosomal recessive genetic disease caused by pathogenic variants in the gene that encodes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein [1]. Defective CFTR protein reduces or abolishes CFTR-dependent chloride and bicarbonate transport in epithelia, leading to a multi-organ disease. In people with CF, lung disease is the main cause of death and involves a vicious circle with highly viscoelastic mucus, leading to mucus plugging, chronic inflammation and bacterial infection in the airways. These factors can lead to airway injury and bronchiectasis, and may progress to respiratory failure. For decades, advancements in CF care have primarily resulted from the refinement of symptomatic therapies such as airway clearance therapies, nutritional management, the use of inhaled and systemic antibiotics, and timely referrals for lung transplantation.
引用
- Burgel PR, Mall MA. Advances in cystic fibrosis: CFTR modulator triple combinations. Eur Respir J. 2026. PMID: 41309268. doi:10.1183/13993003.01783-2025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。